Abstract

<p class="ADMETabstracttext">Gout is a common inflammatory arthritis that is caused by chronically-elevated serum uric acid (sUA) levels (hyperuricemia). In humans, sUA levels are predominantly controlled by a variety of transporters that mediate the elimination of uric acid through the kidneys and intestines, a process that is altered in most gout patients. In this review, we highlight our current understanding of uric acid handling in healthy individuals and gout patients, therapies for gout that target uric acid transporters, and the mechanism of other therapies that alter sUA levels through interactions with uric acid transporters.</p>

Highlights

  • Gout is a debilitating inflammatory arthritis of increasing prevalence that is caused by chronically elevated levels of serum uric acid, or hyperuricemia, defined as concentrations exceeding 6.8 mg/dL (408 μM)

  • Genetic studies show that a large number of urate transporters (GLUT9, ABCG2, NPT1/3/4, URAT1, OAT4, MRP4) are important for urate homeostasis in humans [6,7,8] which are expressed in the organs that eliminate uric acid

  • Dietary purines are imported from the lumen of intestinal enterocytes by the nucleoside transporter CNT2/SLC28A2, which are converted to uric acid by intestinal xanthine oxidase

Read more

Summary

Gout and hyperuricemia

Gout is a debilitating inflammatory arthritis of increasing prevalence that is caused by chronically elevated levels of serum uric acid (sUA), or hyperuricemia, defined as concentrations exceeding 6.8 mg/dL (408 μM). Serum urate levels are normally in the range of 3.5-7 mg/dL (210 – 420 μM) [1]. Prolonged hyperuricemia can initiate the precipitation of the uric acid in joints and other tissues, and these deposits can trigger an acute and painful immune response known as a gout flare. Hyperuricemia is strongly and independently associated with a number of other important disorders including hypertension, cardiovascular disease and metabolic syndrome [2]. A number of therapies for gout that lower sUA levels target transporters for uric acid, some which are important drug transporters

Uric acid homeostasis in humans in health and disease
Tan and Miner
Uric acid transporters and drug interactions
FTHL KKYS
Evolution of gout in humans
Genetics of uric acid
Renal handling of uric acid
Renal uric acid reabsorption
Br N S
Binding of known inhibitors
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.